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Abstract 
Background: Disruption of malaria control strategies during the West African 2014–2016 Ebola epidemic led to an 
increase in malaria‑attributable mortality. However, recent data on malaria infection in vulnerable groups, such as 
pregnant women, are lacking in this post‑Ebola scenario. This cross‑sectional study aimed to assess the prevalence 
of Plasmodium falciparum infection and of molecular markers of drug resistance among pregnant women attending 
antenatal care in Monrovia, capital of Liberia.
Methods: From October 2016 to June 2017, all pregnant women attending their first antenatal care visit at the Saint 
Joseph’s Catholic Hospital, Monrovia, were invited to participate in the study. In addition to their routine antenatal 
care tests, capillary blood spotted onto filter papers were collected from all consenting participants to determine 
presence of P. falciparum by real‑time quantitative PCR. Molecular markers of anti‑malarial drug resistance were 
assessed through Sanger sequencing and quantitative PCR in specimens positive for P. falciparum analysis.
Results: Of the 195 women participants, 24 (12.3%) were P. falciparum‑positive by qPCR. Infected women tended to 
be more commonly primigravidae and younger than uninfected ones. Parasite densities were higher in primigravidae. 
Fever was more frequently detected among the infected women. No statistically significant association between P. fal-
ciparum infection and haemoglobin levels or insecticide‑treated net use was found. While high prevalence of genetic 
polymorphisms associated with chloroquine and amodiaquine resistance were detected, no molecular markers of 
artemisinin resistance were observed.
Conclusion: Plasmodium falciparum infections are expected to occur in at least one in every eight women attending 
first ANC at private clinics in Monrovia and outside the peak of the rainy season. Young primigravidae are at increased 
risk of P. falciparum infection. Molecular analyses did not provide evidence of resistance to artemisinins among the P. 
falciparum isolates tested. Further epidemiological studies involving pregnant women are necessary to describe the 
risk of malaria in this highly susceptible group outside Monrovia, as well as to closely monitor the emergence of resist‑
ance to anti‑malarials, as recommended by the Liberian National Malaria Control Programme.
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Background
Children and pregnant women are particularly vulner-
able to Plasmodium spp. infection and disease, which 
translates into significant negative consequences for the 
health of mothers and infants [1–3]. In Liberia, West 
Africa, malaria transmission is perennial throughout 
the year, and infections are mostly caused by Plasmo-
dium falciparum [4]. According to the 2011 and 2016 
National Malaria Indicator Surveys (MIS), malaria prev-
alence remains high, peaking at 45.0% among children 
6–59 months of age [5, 6].
The Liberian Ministry of Health and Social Wel-
fare (LMoHSW) recommends the use of artemisinin-
based combined therapy (ACT), intermittent preventive 
treatment during pregnancy (IPTp) with sulfadoxine–
pyrimethamine (SP), and provision of insecticide-treated 
nets (ITN) as key strategies for control of malaria in preg-
nancy [7]. As in other sub-Saharan African countries, 
uptake of IPTp remains suboptimal and far from global 
coverage targets [8]. The 2013 national Demographic and 
Health Survey (DHS) reported that 48% of women who 
gave birth in the past 2 years had received two or more 
doses of IPTp-SP and that 37% of pregnant women slept 
under an ITN the preceding night [9].
Both the scale-up of ITN distribution and IPTp-SP, 
as strategies to protect pregnant women from malaria, 
were discontinued during the recent Ebola epidemic that 
resulted in over 10,000 deaths in Liberia, Sierra Leone 
and Guinea Conakry [10–12]. Mathematical modelling 
estimated that the interruption of malaria control could 
have caused a 62% increase in mortality by malaria [13]. 
Pregnant women were particularly affected since many 
stopped attending antenatal care (ANC) services and 
preferred to deliver outside the health facilities [14–16]. 
Fear of becoming infected with Ebola and the decima-
tion of the healthcare workforce to this disease, in addi-
tion with the interruption of regular healthcare services 
added to the financial, geographical and social challenges 
that women were already facing to access healthcare in 
Liberia [11, 17].
Although progress has been made globally in the 
implementation of vector control tools and other preven-
tive tools to decrease the incidence of malaria [18, 19], 
development of insecticide resistance from the vectors 
and of anti-malarial resistance from the parasite might 
hamper the success of available treatment and preven-
tive tools [20, 21]. The real threat posed by the potential 
emergence and/or spread of malaria parasites resistant to 
artemisinin and its derivatives [22], and the need to guide 
the choice of anti-malarial drugs by National Malaria 
Control Programmes, all warrant enhanced molecular 
surveillance to map the prevalence of molecular mark-
ers of resistance, particularly in the absence of regional 
capacities to conduct in vivo clinical trials [23, 24]. Mark-
ers k13 [25–27], pfcrt [28–33], pfmdr1 [31, 34–37] and 
pfdhps [38] are of special interest to Liberia as—since the 
availability of substandard anti-malarials in the Liberian 
market is documented [39]—they could help monitor 
resistance to current LMoHSW-endorsed IPTp-SP and 
artesunate–amodiaquine-based first-line ACT [7].
To date, there is a dearth of studies assessing how inter-
ruption of malaria control and care services during the 
Ebola outbreak might have led to self-treatment with 
substandard anti-malarial drugs bought in local chem-
ists and, as consequence, fuel the appearance of markers 
of parasite resistances. In addition, there are no available 
survey-based data on prevalence of Plasmodium spp. 
infection among pregnant women [5, 6] before and after 
the Ebola outbreak. To inform the design and roll out of 
enhanced malaria prevention and care targeting pregnant 
women in post-Ebola Liberia, baseline descriptive epide-
miological data on prevalence of malaria infection and 




This was an observational cross-sectional study that 
aimed to assess the burden of malaria among pregnant 
women attending ANC in Monrovia. Specific objectives 
of the study included determining the prevalence of P. 
falciparum infection in this particular vulnerable group 
through molecular assays, and assessing molecular mark-
ers of drug resistance in P. falciparum isolates.
Study site and population
The study was conducted at the Outpatients Department 
(OPD) of the not-for-profit Saint Joseph’s Catholic Hos-
pital (SJCH) in Congo Town neighbourhood, Monrovia. 
The SJCH was founded in 1963 by the Hospitaller Order 
of the Brothers of St John of God. In 2014, the SJCH 
closed for 4 months after nine of its staff members died 
to Ebola. Since its reopening in 2015, the SJCH provides 
general services to the population of Monrovia. Although 
the SJCH applies a cost recovery system for the general 
public, the institution has a charity arm to subsidize 
healthcare-related costs for the most deprived ones. Its 
official fee for a first ANC is of 5.00 USD. However, as 
the SJCH is supported by the National HIV and Malaria 
Programmes, diagnostics and therapeutics for HIV/AIDS 
and malaria are provided free-of-charge.
Inclusion criteria set for sampling eligible participants 
at the OPD included: pregnant women of any gestational 
age attending ANC at the SJCH for the first time in their 
current pregnancy. Women unwilling to give consent to 
participate or who reported having received any IPTp 
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dose during their current pregnancy were excluded. 
Calculations indicated that a sample of 198 women was 
needed to detect a prevalence of PCR-confirmed parasi-
taemia of 50% (conservative estimate) with a ± 5% preci-
sion and a confidence level of 95%.
Recruitment and specimen collection
After an initial period of training to the SJCH staff, 
recruitment and specimen collection was done between 
October 2016 and June 2017. All women arriving at the 
OPD who met the inclusion criteria were invited to par-
ticipate and informed of the study objectives and speci-
men collection procedures.
After providing written informed consent, they were 
queried regarding basic socio-demographic and malaria 
prevention-related data (i.e. use of ITN the preced-
ing night, or last time their house was sprayed indoor-
residual insecticides). Participants were also asked to 
volunteer their HIV and tuberculosis status, if known. 
An infrared thermometer was used to measure forehead 
temperature. Gestational age was assessed by date of last 
menstrual period and by measurement of fundal height. 
All data were manually captured by the recruiting mid-
wife using individual standardized case report forms.
All participants were referred to the SJCH Laboratory 
for specimen collection. Results of routine tests done at 
the SJCH laboratory as part of standard ANC care for 
all pregnant women (i.e. HIV, haemoglobin and syphilis) 
were also captured in their case report forms. Haemo-
globin level was obtained using point-of-care Hemocue 
Hb 301 (®Radiometer Group, Ängelholm, Sweden). HIV 
serostatus and syphilis screening were assessed using 
rapid tests SD Bioline HIV-1/2 3.0 (®Alere Inc., Waltham, 
MA) and SD Bioline HIV/Syphilis Duo (®Alere Inc., 
Waltham, MA), respectively.
Laboratory methods
Capillary blood from the women’s fingers was collected 
on two Whatman 903 filter papers that were shipped to 
ISGlobal Laboratory (Barcelona, Spain) for molecular 
testing. The presence of P. falciparum was determined 
by real-time Quantitative PCR (qPCR). Briefly, DNA 
extracted by Chelex method from the filter paper was 
used for detection of 18S rRNA in duplicate [40, 41]. 
Parasite density was quantified by extrapolation of cycle 
thresholds (Ct) from a standard curve of P. falciparum 
ring-infected erythrocytes. A negative control with no 
template DNA was run in all reactions.
Samples that tested positive for P. falciparum were 
subjected for the analysis of molecular markers of anti-
malarial drug resistance using previously described 
methods [42–44]. DNA from samples with less than 
5  parasites/μL was subjected to pre-amplification using 
PicoPLEX WGA Kit (®Rubicon Genomics: Cat. No. 
—R30050) as per manufacturer’s instructions. DNA 
templates were then subjected to PCR amplification of 
molecular markers of k13, pfcrt, pfmdr1 and pfdhps genes 
using a 2720 thermal cycler (®Applied Biosystems) fol-
lowed by direct DNA Sanger sequencing bi-direction-
ally [44]. A set of primer pair (Fw: caaattctatagtgtagttc; 
Rv: aattgtgtgatttgtccacaa) was used to sequence pfdhps 
522–646 amino acid positions. For pfpm2 and pfmdr1 
genes, copy number (CN) was also determined by SYBR-
based qPCR (2× Power SYBR Green PCT Master Mix; 
®Thermo Fisher Scientific, Washington, WA, UK) [44, 
45]. All samples with estimated CN > 1.5 were repeated 
for confirmation. Water and human genomic DNA were 
used as negative controls. A total of six positive controls 
with known k13 alleles; four parasite lines (3D7, 7G8, 
Dd2 and V1/S) with known pfcrt and pfmdr1 alleles; 
four plasmids (DHPS-V1S, DHPS-PERU, DHPS-MALI 
and DHPS-DD2) with known pfdhps alleles; one posi-
tive control (C4) with known copies (3–4) of pfpm2 gene; 
another positive control (Dd2) with known copies (3–4) 
of pfmdr1 were also processed, amplified and sequenced. 
Isolates with mixed alleles were considered as mutated 
for the purposes of polymorphism frequency estimation.
Data management
A unique identification number was used to link signed 
consent forms to case report forms. Case report forms 
did not include personal identifiers and were used to col-
lect socio-demographic, malaria care-related data, and 
ANC routine laboratory tests data. Data from the case 
report forms were digitized by a SJCH trained clerk into 
an online case record form manager built in open source 
software OpenClinica (®OpenClinica LLL., Waltham, 
MA) and kept safely in a locked cabinet at the SJCH. 
ISGlobal Laboratory data were directly captured by the 
laboratory technician into the OpenClinica-generated 
dataset. Access to OpenClinica was password protected. 
OpenClinica server is kept at the Hospital Clínic (Barce-
lona, Spain) server.
Definitions and statistical analysis
All blood specimens collected were included in the qPCR 
analysis. A positive P. falciparum infection in peripheral 
blood by qPCR, irrespective of parasite density, was the 
primary outcome in the analysis presented in this paper. 
Fever was defined as temperature ≥ 38 °C, and maternal 
anaemia as haemoglobin levels < 11 mg/dL (being mild if 
between 10 and 10.9 mg/dL, moderate if between 7 and 
9.9 mg/dL, and severe if < 7 mg/dL). Women were clas-
sified as primigravidae (first pregnancy) or multigravidae 
(at least one previous pregnancy).
Page 4 of 10Martínez‑Pérez et al. Malar J  (2018) 17:357 
Cross tabulations and t-test, Pearson Chi squared test 
(χ2) or Fisher’s exact test were used, where appropriate, to 
explore whether socio-demographics and other health-
related variables of interest were associated with P. fal-
ciparum infection. Data analysis was conducted using 
STATA v.12.0 (®StataCorp LLD., College Station, Texas, 
USA). Significance level was set at p < 0.05.
Ethics
The study was conducted in accordance with the ICH 
E6 Good Clinical Practice [46], and under the provisions 
of the Declaration of Helsinki [47], and local rules and 
regulations. Written informed consent was sought for 
all women if 18  years of age or older. Parental consent 
in addition to minor assent was sought for all women 
aged younger than 18 years. Participants did not receive 
any retribution for their engagement as study subjects. 
Refusal to participate in this study did not affect ser-
vice provision as per standard ANC practice. All women 
invited to enrol in this study, both consenting and non-
consenting, received their first dosage of IPTp and treat-
ment for anaemia, if necessary.
This research protocol was approved by the local Uni-
versity of Liberia-Pacific Institute Research and Evalu-
ation Institutional Review Board (UL-PIRE, Monrovia, 
Liberia) and by the Hospital Clínic Health Research Eth-
ics Committee (CEIC, Barcelona, Spain).
Results
One hundred and ninety-eight women meeting inclu-
sion criteria were invited to participate, and all of them 
consented. Of the 198 women enrolled, three decided to 
discontinue their participation before collection of blood 
specimens. The analysis presented is based on data from 
the 195 women with peripheral blood samples available 
and analysed for P. falciparum infection.
Clinical and socio‑demographics characteristics of study 
women
All participants were residents of Monrovia and peri-
urban areas. Their mean age was 27.3  years (stand-
ard deviation [SD] 6.1; range 14–43) and 7 (3.6%) were 
younger than 18 years of age. More than half (57.9%) of 
the participants had concluded secondary studies and 
15% had not completed any education (Table  1). One 
in four women (26.7%) were students with no source of 
income, whilst one third of the total (34.9%) were self-
employed in the sales and services sector.
Over a fourth (27.3%) of the participants were primi-
gravidae (Table  1). Multigravidae women (n = 141) 
reported an average of 3.5 (range 2–10) pregnancies. 
Mean gestational age at first ANC visit was 17 weeks (SD 
7.14).
Table 1 Clinical and  socio-demographic profile of  study 
women
n number of participants
Variables n (%)
Age (in years) range (n  = 191)
 ≤ 17 7 (3.7%)
 18–25 65 (34.0%)
 26–35 92 (48.2%)
 ≥ 36 27 (14.1%)
 Mean (SD) 27.3 (6.10)
Anaemia (n  = 193)
 Normal range (≥ 11 mg/dL) 113 (58.5%)
 Anaemia (< 11 mg/dL) 80 (41.5%)
 Mean haemoglobin levels (SD) 11.2 (1.42)
Gravidity (n = 194)
 Primigravidae 141 (27.3%)
 Multigravidae 53 (72.7%)
Gestational age (n  = 186)
 Mean (SD) 17.7 (7.14)
Fever (n  = 188)
 No 182 (96.8%)
 Yes, ≥ 38 °C at point of enrolment 6 (3.2%)
Anti‑malarial use (n  = 195)
 Not in the current pregnancy 140 (71.8%)
 Yes in the current pregnancy 55 (28.2%)
Tuberculosis (n  = 195)
 Not on TB treatment 193 (99.0%)
 Self‑reported on TB treatment 2 (1.0%)
HIV (n  = 167)
 Confirmed negative test 162 (97.0%)
 Confirmed positive test 5 (3.0%)
Syphilis (n  = 160)
 Confirmed negative test 159 (99.4%)
 Confirmed positive test 1 (0.6%)
ITN (n  = 195)
 Did not use an ITN the preceding night 139 (71.3%)
 Slept under an ITN the preceding night 56 (28.7%)
Education completed (n  = 186)
 None 25 (14.6%)
 Primary 24 (14.0%)
 Secondary 97 (56.7%)
 Tertiary/college 1 (0.6%)
 University 17 (9.9%)
Current occupation (n  = 194)
 Professional/technological 12 (7.0%)
 Sales/services: self‑employed 62 (36.3%)
 Sales/services: salaried 12 (7.0%)
 Skilled/unskilled manual 14 (8.2%)
 Clerical 4 (2.3%)
 Student (no other paid occupation) 43 (25.2%)
 Unemployed 23 (13.5%)
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Of the 193 women with haemoglobin test results, 29 
(14.9%) and 51 (26.1%) had moderate and mild anaemia, 
respectively. No severe anaemia cases were detected. 
Six women (3.2%) had fever, and 55 (28.2%) self-
reported having had taken anti-malarials in their current 
pregnancy.
Only two participants (1%) reported being on treat-
ment for tuberculosis. No participant reported being 
HIV-infected. Of the 167 women who received an HIV 
rapid test, five (3.0%) had a confirmatory positive result. 
Among the 160 women who agreed to test for syphilis, 
only one (0.6%) was positive (Table 2).
All women but two (98.9%) reported that their home 
was never targeted in an indoor residual spraying pro-
gram. Two-thirds of the total (71.3%) reported that they 
had not slept under an ITN the preceding night.
Prevalence of Plasmodium falciparum infection 
and association with demographic and health‑related 
variables
Twenty-four women (12.3%) were confirmed as P. fal-
ciparum positive by qPCR (Table  2). Parasite densities 
tended to be lower in multigravidae than in primigravi-
dae (Fig. 1). Low density P. falciparum infections (para-
site densities below 10 parasites/µL) were more frequent 
among multigravidae (62% [8/13]) than among primi-
gravidae (18% [2/11]; p = 0.047).
Compared to the uninfected women (Table 2), P. falci-
parum-infected women were significantly younger (24.9 
vs. 27.6  years; p = 0.044) and in their first pregnancy 
(45.83 vs. 24.7%; p = 0.030). No associations between 
infection and education or occupation were found.
No statistically significant differences in terms of hae-
moglobin levels were found between the P. falciparum-
infected (mean 10.89; range 9.2–13.7) and uninfected 
women (mean 11.26; range 7–16; Table 2). In total, 50.0% 
and 40.2% of the P. falciparum-infected and the unin-
fected women had anaemia, respectively (p = 0.364). 
Occurrence of fever was significantly more frequent 
among the infected women (14.3% vs. 1.8%; p = 0.019). 
No associations were found between P. falciparum infec-
tion and self-reported tuberculosis status, positive syphi-
lis test, positive HIV test, and the use of ITNs (Table 2).
Molecular markers of anti‑malarial resistance
Of the 24 samples positive for P. falciparum by qPCR, 
17 (70.8%) and 11 (45.8%) were successfully analysed 
for polymorphisms (k13, pfmdr1, pfdhps and pfcrt) and 
copy number (pfpm2 and pfmdr1), respectively (Table 3). 
Sequencing analysis of all laboratory positive controls 
with known alleles revealed the presence of wild and 
mutant-type alleles of k13, pfmdr1, pfcrt and pfdhps 
polymorphisms. The estimated pfpm2 and pfmdr1 copy 
number for the laboratory positive controls (C4 and Dd2) 
were between 3 and 4 copies using  SYBR®-based qPCR. 
The qPCR assays were specific to P. falciparum gDNA 
only, as no amplifications were noticed in negative con-
trols (with water and human genomic DNA).
The proportion of the pfdhps polymorphisms S436F, 
A437G, A581G and A613S described as associated with 
sulfadoxine resistance was 29.4% (5/17), 17.6% (3/17), 
5.9% (1/17) and 11.8% (2/17), respectively. All the iso-
lates had wild-type allele at K540E polymorphism of 
pfdhps gene. In the pfcrt gene, mutant alleles were found 
at codons M74I, N75E and K76T [88.2% (15/17)]. Two 
novel synonymous polymorphisms (I77I and I103I [5.9% 
(1/17)]) were observed in the pfcrt gene. A total of four 
polymorphisms were identified across the pfmdr1 gene. 
The prevalence of N86Y, L155L, Y184F and D1246Y 
mutant alleles was 47.1% (8/17), 5.9% (1/17), 58.8% 
(10/17) and 11.8% (2/17), respectively. The other most 
frequent S1034C and N1042D polymorphisms of pfmdr1 
gene were not observed. The most frequent polymor-
phisms in k13 observed previously in Cambodian isolates 
[25] were absent in the P. falciparum isolates analysed. 
However, a novel synonymous polymorphism V510V 
[5.9% (1/17)] was observed. All the isolates carried a sin-
gle copy of pfpm2 and pfmdr1 genes.
Discussion
This appears to be the first study conducted in Liberia 
assessing the prevalence of P. falciparum infection among 
pregnant women after the Ebola epidemic that led to 
the interruption of malaria control [10, 13]. This study 
found a 12.3% prevalence of P. falciparum (by qPCR) 
among pregnant women attending to their first ANC visit 
at a non-government hospital in Monrovia, and before 
administration of any IPTp-SP dose. Molecular analysis 
of genetic markers of anti-malarial resistance showed no 
compromised therapeutic efficacy of ACT, but suggests 
suboptimal prevention by SP provided as IPTp.
Young primigravidae had the highest burden of P. fal-
ciparum infection at first antenatal visit. Similarly, low 
density infections were more common in multigravidae 
than in primigravidae women. This difference was not 
due to increased use of ITNs among the multigravidae. 
Rather, this observation is in line with the concept that 
the lack of immunity to the antigenic variants presented 
by P. falciparum parasites that accumulate selectively in 
the placenta increases the risk of P. falciparum infection 
in primigravidae [48–50]. However, this prevalence is 
much lower than the prevalence observed in the national 
2016 MIS among children aged 6–59 months (26.9% and 
61.9% by RDT in urban and rural areas respectively) [6]. 
Use of ITN among our participants (28%) was slightly 
lower than was reported at the 2013 DHS (37%) [9] and 
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Table 2 Health-related data and laboratory examinations
n number of participants




Variables Uninfected (n  = 171, 87.7%)a P. falciparum infection (n  = 24, 12.3%)a p
n (%) n (%)
Age (n  = 191)
 Mean (SD) 27.6 (SD 5.88) 24.9 (7.19) 0.045b
Anaemia (n  = 193)
 Mean haemoglobin levels (SD) 11.26 (1.45) 10.89 (1.13) 0.231b
Gravidity (n  = 194)
 Multigravidae 128 (75.3%) 13 (54.2%)
 Primigravidae 42 (24.7%) 11 (45.8%) 0.030c
Gestational age (n  = 195)
 1st trimester (1–14 weeks) 59 (34.5%) 10 (41.7%)
 2nd trimester (15–28 weeks) 100 (58.5%) 11 (45.8%)
 3rd trimester (≥ 29 weeks) 12 (7.0%) 3 (12.5%) 0.423c
Fever (n  = 188)
 No 164 (98.2%) 18 (85.7%)
 Yes, ≥ 38 °C at point of enrolment 3 (1.8%) 3 (14.3%) 0.019d
Anti‑malarial use (n  = 195)
 Not in the current pregnancy 123 (71.9%) 17 (70.8%)
 Yes in the current pregnancy 48 (28.1%) 7 (29.2%) 0.911c
Tuberculosis (n  = 195)
 Not on TB treatment 170 (99.4%) 23 (95.8%)
 Self‑reported on TB treatment 1 (0.6%) 1 (4.2%) 0.232d
HIV rapid test (n  = 167)
 Confirmed negative test 143 (97.9%) 19 (90.5%)
 Confirmed positive test 3 (2.0%) 2 (9.5%) 0.119d
Syphilis rapid test (n  = 160)
 Confirmed negative test 140 (100.0%) 19 (95.0%)
 Confirmed positive test 0 (0.0%) 1 (5.0%) 0.125d
ITN (n  = 195)
 Did not used an ITN the preceding night 123 (71.9%) 16 (66.7%)
 Slept under an ITN the preceding night 48 (28.1%) 8 (33.3%) 0.594c
Education completed (n  = 186)
 None 25 (14.6%) 3 (12.5%)
 Primary 24 (14.0%) 2 (8.3%)
 Secondary 97 (56.7%) 16 (66.7%)
 Tertiary 1 (0.6%) 0 (0.0%)
 University 17 (9.9%) 1 (4.2%) 0.800c
Current occupation (n  = 194)
 Professional/technological 12 (7.0%) 2 (8.3%)
 Sales/services: self‑employed 62 (36.3%) 6 (25.0%)
 Sales/services: salaried 12 (7.0%) 2 (8.3%)
 Skilled/unskilled manual 14 (8.2%) 1 (4.2%)
 Clerical 4 (2.3%) 0 (0.0%)
 Student (no other paid occupation) 43 (25.2%) 9 (37.5%)
 Unemployed 23 (13.5%) 4 (16.7%) 0.420c
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at the 2016 MIS (35% in urban areas) [6]. Half of the P. 
falciparum-infected women (50.0%; see Table 2) had sub-
clinical malaria (i.e. without fever, anaemia) and could 
sustain malaria transmission [51].
Genetic polymorphisms associated with parasite 
resistance to chloroquine and pyrimethamine were 
detected in rural Liberia as early as 1978 [52]. Three 
decades later, resistance to chloroquine and SP con-
tinued to rise [53]. In 2003, national policies endorsed 
ACT with artesunate–amodiaquine as first treatment 
option for P. falciparum uncomplicated malaria [5]. 
In this study, a high prevalence of K76T, N86Y, Y184F 
and D1246Y (pfcrt and pfmdr1) polymorphisms previ-
ously associated with resistance to chloroquine and to 
artesunate–amodiaquine (88.2, 47.1, 58.8 and 11.8%, 
respectively) was observed [29, 31, 32, 54, 55]. In con-
trast, prevalence of molecular markers of resistance 
to the sulfadoxine component of SP—considering 540 
as a surrogate of quintuple mutants in Africa [56]—
was relatively low, in accordance with molecular data 
obtained in the region [57]. The prevalence data of 
polymorphisms align with previously published data 
generated from the only recent study that collected 
pre-treatment isolates from children below 5  years of 
age, and reported occurrence of polymorphisms associ-
ated to current ACT used in Liberia [31]. In the present 
study, only one synonymous k13 polymorphism was 
observed among the P. falciparum isolates tested, thus 
demonstrating the absence of genetic evidences of arte-
misinin resistance in the parasite population circulating 
in Monrovia.
To strengthen malaria control in post-Ebola Liberia, 
enhanced surveillance and community-tailored health 
promotion is deemed urgent. Given the significant 
investment in PCR equipment during the Ebola epi-
demic in Liberia, surveillance could be enhanced by 
improving capacities at multiple sentinel sites. Indeed, 
the addition of PCR-based diagnostics to detect P. fal-
ciparum was considered feasible and did not pose addi-
tional safety risks to staff during the Ebola outbreak 
[58]. Continuous surveillance of malaria at ANC could 
be useful to assess temporal trends in the burden of 
malaria, to promptly detect emergence of anti-malar-
ial resistance, and to provide prevention, treatment 
and health education to the pregnant women at risk of 
malaria infection [59].
Accompanying these surveillance efforts with clinic 
and community-based health promotion could improve 
the success of control and preventive measures against 
malaria. As reported in a qualitative study conducted 
in Monrovia in parallel to this prevalence study, many 
pregnant women may see their access to malaria care 
impeded due to low perception of their increased risk to 
malaria and to avoid unofficial fees requested by health 
staff at government-run clinics [60]. As a result, many 
women may resort to traditional herbal medicine or may 
opt to self-medicate with substandard anti-malarials 
that are easily available in the local chemists. All these 
practices and attitudes could lead to the worsening of 
the symptomatology and prognosis of their malaria dis-
ease and to the appearance of resistances to LMoHSW-
endorsed anti-malarial regimes, and must be considered 
in the planning of malaria control activities in Liberia.
Fig. 1 Plasmodium falciparum densities according to gravidity
Table 3 Molecular markers of  P. falciparum anti-malarial 
resistance
SNP single nucleotide polymorphisms, Syn synonymous mutation (no amino 
acid change)
Genes SNP Wild‑type Mutant
Pfmdr1
Multi‑drug resistance
N86Y 8 (47.0%) 9 (52.9%)
L155L (Syn) 16 (94.1%) 1 (5.9%)
Y184F 7 (41.2%) 10 (58.8%)
S1034C 17 (100.0%) 0 (0%)
N1042D 17 (100.0%) 0 (0%)
D1246Y 15 (88.2%) 2 (11.8%)
Pfdhps
Sulfadoxine
S436A 12 (70.6%) 5 (29.4%)
A437G 14 (82.3%) 3 (17.6%)
K540E 17 (100.0%) 0 (0%)
A581G 16 (94.1%) 1 (5.9%)
A613S 15 (88.2%) 2 (11.8%)
Pfcrt
Chloroquine
M74I 2 (11.8%) 15 (88.2%)
N75E 2 (11.8%) 15 (88.2%)
K76T 2 (11.8%) 15 (88.2%)
I77I (Syn) 16 (94.1%) 1 (5.9%)
I103I (Syn) 16 (94.1%) 1 (5.9%)
K13
Artemisinin
V510V (Syn) 16 (94.1%) 1 (5.9%)
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Limitations
An important limitation to consider is that the recruit-
ment period took place from October to June. Hence, 
no participant was recruiting during the peak months 
of the rainy season, which may justify the relatively 
low prevalence observed. Another limitation is that 
this study was conducted in an institution that charges 
pregnant women for the first ANC, a factor that could 
have limited recruitment of certain women who may 
be more prone to exposure to malaria infection. The 
findings of this study might be extrapolated only to 
the group of women of low-middle class with access to 
employment and education.
Additionally, recall bias could have compromised par-
ticipants’ self-reporting of previous use of malaria pre-
vention and treatment. Potential effect of recall bias was 
minimized by intensive training on study specific proce-
dures for data collection to the recruiting staff.
Conclusion
In conclusion, P. falciparum infections are expected in 
at least one in every eight women attending first ANC 
at a non-Government-run facility in Monrovia and out-
side the peak of the rainy season. The risk of P. falcipa-
rum infection is higher among young primigravidae. No 
genetic evidence of resistance to artemisinins was found 
among the P. falciparum isolates tested. More epidemio-
logical studies involving pregnant women in Liberia are 
needed to describe the risk of malaria in this highly sus-
ceptible group in other settings in the country, as well as 
to closely monitor the emergence of resistance to com-
monly used anti-malarials in-country.
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